At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,294 enrolled
Drug / intervention
risedronate +1 moredrug
Likely dose
risedronate 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III, Multicenter, Double-blind, Randomized, Active-controlled, Parallel Group, Non-inferiority Study Comparing 150 mg Risedronate Monthly With 5 mg Risedronate Daily in the Treatment of Postmenopausal Osteoporosis (PMO)
In Brief
A Phase 3 clinical trial evaluating risedronate for Postmenopausal Osteoporosis. Completed, enrolled 1,294 participants across 49 sites in 14 countries.
Detailed Summary
The purpose of this trial is to study the efficacy of a single-dose monthly dosing regimen as compared to the standard daily dosing regimen of risedronate 5 mg daily.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPostmenopausal Osteoporosis
CountriesArgentina, Australia, Belgium, Brazil, Canada, Estonia, Finland, France, Hungary, Lebanon, Norway, Poland, Spain, United States
CollaboratorsSanofi
Timeline
Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartOct 2005
First PostedNov 2005
Primary CompletionMar 2008
Study CompletionApr 2008
TodayJul 2026
First PostedNov 1, 2005
Enrollment StartOct 1, 2005
Primary CompletionMar 1, 2008
Study CompletionApr 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 20.7 years ago
Interventions
risedronatedrug
tablet, 5 mg risedronate, once a day for 2 years
risedronatedrug
oral, 150 mg risedronate, once a month for 2 years